Skip to main content
. 2022 Apr 19;9:20543581221090010. doi: 10.1177/20543581221090010

Table 1.

A Description of Individual Adult Patients From the Existing Literature With Resistant FSGS Treated With Rituximab and Their Associated Outcome.

Reference Sex Ethnicity FSGS Histological Subtype Age a (Years) Previous Therapies Duration of Disease
(years)		 Steroid-Sensitive RTX Dosage Proteinuria Prior to RTX Proteinuria After RTX SCr Prior to RTX (umol/L) SCr After RTX (umol/L) Albumin Prior to RTX (g/L) Albumin After RTX (g/L) Follow-up Time (Months) Status at Last Follow-up
Fernandez-Fresnedo et al. 5 M N/A NOS 19 CST, TAC, MMF 2 No 375 mg/m2 weekly × 4 16g/d 14 g/d 106.1 168.0 — — 12 No response
Fernandez-Fresnedo et al. 5 M N/A Tip 29 CST, CYC, CsA, MMF 3 No 375 mg/m2 weekly × 4 16.5g/d 21 g/d 79.6 70.7 — — 12 No response
Fernandez-Fresnedo et al. 5 M N/A NOS 34 CST, CsA, TAC, MMF 3 No 375 mg/m2 weekly × 4 9.4g/d 11.3 g/d 123.8 123.8 — — 14 No response
Fernandez-Fresnedo et al. 5 M N/A NOS 19 CST, CsA, MMF 1.1 No 375 mg/m2 weekly × 4 12g/d 14 g/d 79.6 97.2 — — 18 No response
Fernandez-Fresnedo et al. 5 M N/A NOS 55 CST, CsA 2 No 375 mg/m2 weekly × 4 9.8g/d 10.5 g/d 79.6 70.7 - - 24 No response
Fernandez-Fresnedo et al. 5 M N/A Cellular variant 51 CST, CsA, MMF 8.9 No 375 mg/m2 weekly × 4 12.7g/d 9.0 g/d 203.3 221 — — 24 No response.
Fernandez-Fresnedo et al. 5 M N/A NOS 20 CST, CsA, TAC, MMF 2.5 No 375 mg/m2 weekly × 4 12.9g/d 3.2 g/d 150.2 141.4 — — 12 Response
PR with tapering of CST, TAC, and MMF.
Fernandez-Fresnedo et al. 5 F N/A NOS 23 CST, CYC, CsA, MMF 7.9 No 375 mg/m2 weekly × 8 23g/d 3.9 g/d 168.0 141.4 — — 15 No response
Ochi et al. 10 F N/A Collapsing 25 CST, CsA, Mizoribine 12 No 375 mg/m2 single dose 6.5g/d 6-8 g/d 114.9 — — — — No response
Ochi et al. 10 M N/A NOS 21 CST, CsA, CYC, MMF 9 No 375 mg/m2 single dose 13g/d 15-20 g/d 185.6 — — — — No response
Ochi et al. 10 F N/A Perihilar 27 CST, CsA 18 Yes 375 mg/m2 × 4 doses 9.8g/d 0-1 g/d 44.2 — — — — Response
CR not on other IS agents
Ochi et al. 10 F N/A Tip 26 CST, CsA, CYC, MMF 19 Yes 375 mg/m2 × 3 doses 3.6g/d 0-1 g/d 35.4 — — — — Response
CR not on other IS agents
Marasà et al. 11 F White NOS 22 CST, CYC, Azathioprine 1 No 375 mg/m2 and a second dose 32 months after 4g/d 0.27 g/d 71.6 48.6 26.8 38 48 Response
CR and off other IS agents.
Kisner et al. 12 M N/A N/A 51 CST, CsA 0.6 No 1000 mg single dose 1105.9 mg/mmol 441.3 mg/mmol 136.1 — — — 8 No response
Kisner et al. 12 M N/A N/A 50 CST, CsA, TAC, MMF 2 Yes 1000 mg × 2 doses 485.6 mg/mmol 185.43 mg/mmol 110.5 — — — 22 Response
PR maintained with CST, MMF, TAC.
Peters et al. 13 M N/A N/A 20 CSA, CST, MMF, TAC 8 Yes 1000 mg × 2 doses with 2 week interval between doses 1g/d “Nephrotic range proteinuria persisted” 170 “Renal function rapidly deteriorated” — — 7 No response
Cortazar et al. 14 M N/A N/A 56 CST, CsA, TAC, MMF N/A Yes Initially 1000 mg × 2 doses every 2-4 weeks and then every 4 months after 463 mg/mmol <113 mg/mmol 97.2 88-132 32 40-50 83 Response
PR
Cortazar et al. 14 M N/A N/A 67 CST, MMF N/A Yes Initially 1000mg × 2 doses every 2-4 weeks and then every 4 months after 441 mg/mmol 226-452 mg/mmol 114.9 111-133 — 30-40 70 No response
Based on proteinuria, however prednisone was tapered off.
Cortazar et al. 14 F N/A N/A 67 CST, CsA N/A Yes Initially 1000 mg × 2 doses every 2-4 weeks and then every 4 months after 655 mg/mmol 0 mg/mmol 106 66-88 32 40-50 31 Response
CR
Cortazar et al. 14 F N/A N/A 54 CST, CsA, TAC, MMF, Abatacept N/A Yes Initially 1000 mg × 2 doses every 2-4 weeks and then every 4 months after 554 mg/mmol 0-113 mg/mmol 70.7 44-88 22 37.5-40 13 Response
PR
Cortazar et al. 14 F N/A N/A 65 CST, CsA, MMF N/A No Initially 1000 mg × 2 doses every 2-4 weeks and then every 4 months after 1559 mg/mmol 226-339 mg/mmol 144.4 155-177 23 30-40 29 Response
PR
Cortazar et al. 14 F N/A N/A 66 CST, CYC, MMF N/A No Initially 1000 mg × 2 doses every 2-4 weeks and then every 4 months after 904 mg/mmol 226-339 mg/mmol 114.9 44-88 31 37.5-40 24 Response
PR
Wee Leng et al. 15 M N/A NOS 21 CST, CYC, CsA, MMF 3 Yes 500 mg × 4 doses 1 dose weekly, then 500mg × 6 doses 1 dose weekly 1200 mg/mmol 0-250 mg/mmol 100-150 0-100 19 — — Response
PR
Jayaraman and Thomas 16 M White N/A 62 CST, CsA, CYC 2 No 375 mg/m2 × 4 doses total 200-400 mg/mmol 800-900 mg/mmol 100-200 100-200 25-30 15-20 21 No response
Ramachandran et al. 17 M N/A Collapsing 19 CST, CYC, CsA, MMF, TAC 1.5 No 375 mg/m2 × 4 doses 1 dose weekly 5g/d 1.2 g/d 62-80 80 <20 47 18 Response
PR
Kronbichler et al. 18 F N/A N/A 33 CST, CsA, CYC, MMF, TAC 29 Yes 375 mg/m2 × 4 doses 1 dose weekly, and then 23 months later another 4 doses 1 weekly 689 mg/mmol 4.6 mg/mmol 67.2 68.9 — 48.5 55 Response
CR and off other IS agents.
Kronbichler et al. 18 M N/A N/A 32 CST, CsA, MMF 14 Yes 375 mg/m2 × 4 doses 1 dose weekly 847.5 mg/mmol 9.6 mg/mmol 56.6 50.3 15.9 68 14 Response
CR and off other IS agents.
Kronbichler et al. 18 M N/A N/A 26 CST, CsA, CYC, MMF 2.6 Yes 375 mg/m2 × 4 doses 1 dose weekly Not detectable 6.4 mg/mmol 112.3 79.6 38 40 29 Response
CR and off other IS agents.
Butterly et al. 19 M N/A N/A 32 CST, MMF N/A N/A 1400 mg 1600 mg/mmol 465 mg/mmol — — <15 30 4 No response
Barbour et al. 8 F Asian NOS 41 CST, MMF, TAC, Galactose, CsA 32 No 375 mg/m2 weekly × 4 doses and single 375mg/m2 with CD20 reconstitution 4.95g/d 2.1 mg/mmol
(ACR)		 71 81 23 42 47 Response
CR and off other IS agents.
Barbour et al. 8 M White NOS 21 CST, MMF, TAC, CsA, CYC, Infliximab, Galactose 8 No 375 mg/m2 weekly × 4 doses and single 375mg/m2 with CD20 reconstitution 8.69g/d 55 mg/mmol
(ACR)		 168 270 30 36 55 Response
PR and off other IS agents.
Barbour et al. 8 F White NOS 26 CST, CYC, CsA, TAC 12 Yes 1 g every 2 weeks for 2 doses and single 1g dose with CD20 reconstitution 0.38g/d 0.79 g/d 63 70 35 38 30 Response
PR off CST and with tapering TAC.
Barbour et al. 8 M Asian NOS 19 CST, Chlorambucil, Levamisole, CYC, MMF, TAC 17 No 375 mg/m2 weekly × 4 doses
and single 375 mg/m2 with CD20 reconstitution		 8.30g/d 0.66 g/d 233 91 12 43 40 Response
PR off CST and other IS agents.

Note. FSGS = focal segmental glomerulosclerosis; RTX = rituximab; SCr = serum creatinine; N/A = not available; NOS = not otherwise specified; CST = corticosteroids; TAC = tacrolimus; MMF = mycophenolate mofetil; CYC = cyclophosphamide; CsA = cyclosporine.

a

Age at RTX Administration.